Business Context and Reporting Period
This Form 8-K was filed by Rocket Pharmaceuticals, Inc. on April 4, 2023, reporting executive leadership changes effective on that date. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Market under the symbol RCKT.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensatory arrangements.
Material Changes
- Jonathan Schwartz: Transitioned from Chief Medical Officer to the newly created role of Chief Gene Therapy Officer. His new responsibilities include leading gene therapy and rare disease strategic activities and assessing commercial applications of research.
- Mark White: Appointed as the new Chief Medical Officer. He previously served as Global Franchise Head for Fasenra at AstraZeneca plc since March 2020.
Compensatory Arrangements and Outlook
Mr. White's appointment includes the following compensation package:
- Base Salary: $450,000 annually.
- Target Bonus: 45% of base salary.
- Equity Grant: Approximately $2,000,000 in total value, split as follows:
- One-third in stock options (exercise price equal to closing price on grant date).
- Two-thirds in restricted stock units (RSUs).
- Vesting Schedule: One-third vests on the one-year anniversary of the grant date; the remaining two-thirds vest in eight quarterly increments over the following two years, subject to continued employment.
The filing does not contain specific guidance, risk factors, or contingencies beyond the standard disclosure that Mr. White is an "at will" employee.
Investor Verification Checklist
- Verify the impact of the leadership transition on the company's gene therapy and rare disease pipeline.
- Review the dilution impact of the $2,000,000 equity grant to Mr. White.
- Confirm the vesting conditions and potential forfeiture risks associated with the new executive's equity package.
- Assess Mr. White's prior experience at AstraZeneca and MedImmune relative to Rocket Pharmaceuticals' current clinical programs.